- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Arrowhead Research Corporation announced today that its majority-owned subsidiary, Unidym, has signed a strategic alliance agreement with Battelle, a global science and technology enterprise that develops and commercializes technologies. Under the alliance agreement, Unidym and Battelle will explore opportunities to leverage their respective capabilities to commercialize nanotube-based products. Battelle will also have the option of investing up to $2 million in Unidym's next round of financing.
"Arrowhead is pleased to be working with an organization with the global standing, technical expertise and product development experience of Battelle," stated Art Swift, President and CEO of Unidym. "Our partnership could facilitate more rapid commercialization of disruptive nanotube-based products in different industries."
"Unidym is well positioned to commercialize carbon nanotubes in a broad range of markets," explained Alex Kawczak, VP of Nanotechnology at Battelle. "The combination of Unidym's IP portfolio and expertise in CNT production and CNT-based electronics combined with Battelle's IP and experience in areas ranging from composite materials to fuel cells makes this a very powerful alliance."
Battelle President and CEO Carl Kohrt added, "Battelle continues to invest in nanomaterials technology platforms that are designed to be coupled with innovation alliances that are market-driven. The strategic alliance with Unidym is an example of a multi-laboratory collaboration focused on developing and commercializing carbon nanotube-based products into high-value electroactive nanomaterials product-market segments."
Unidym is a leader in the manufacture and application of carbon nanotubes (CNTs), a novel material with extraordinary electrical, thermal, and mechanical properties. Unidym provides bulk materials, CNT-enabled products, and intellectual property to a wide range of customers and business partners. As a result of its recent merger with CNI, Unidym possesses a foundational patent portfolio that covers nearly every aspect of CNT manufacturing and processing as well as multiple product applications.
Unidym is focused on the electronics industry where its initial products include transparent electrodes for touch screens, flat panel displays, solar cells, and solid state lighting; electrodes for fuel cells; and thin film transistors for printable electronics. Unidym is also pursuing an aggressive, cross-industry partnership strategy to capture value from the wide ranging uses of CNTs. Unidym's licensing program, technical expertise and manufacturing facilities can enable partners to rapidly develop CNT solutions for their specific applications.
About Arrowhead Research Corporation
Arrowhead Research Corporation (www.arrowheadresearch.com) is a publicly-traded nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead is building value for shareholders through the progress of majority owned subsidiaries founded on nanotechnologies originally developed at universities. The company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Currently, Arrowhead has four subsidiaries commercializing nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, carbon-based electronics and compound semiconductor materials.
Battelle is the world's largest non-profit independent research and development organization, with 20,000 employees in more than 120 locations worldwide, including five national laboratories Battelle manages or co-manages for the U.S. Department of Energy. Headquartered in Columbus, Ohio, Battelle conducts $3.8 billion in R&D annually through contract research, laboratory management, and technology commercialization. As a non-profit charitable trust with an eye toward the future, Battelle actively supports and promotes science and math education. For more information visit www.battelle.orgor contact Media Relations Manager Mark Berry at 614-424-5544 or at
Safe Harbor Statement under the Private Securities Litigation Reform
Act of 1995
This news release contains forward-looking statements within the
meaning ofthe "safe harbor" provisions of the Private Securities
Litigation Reform Actof 1995. These statements are based upon our
current expectations and speak onlyas of the date hereof. Our actual
results may differ materially and adversely from those expressed in
any forward-looking statements as a result of various factorsand
uncertainties, including the future success of our scientific
studies, our ability to successfully develop products, rapid
technological change in our markets, changes in demand for our future
products, legislative, regulatory and competitive developments and
general economic conditions. Our Annual Report on Form 10-K and
10-K/A, recent and forthcoming Quarterly Reports on Form 10-Q and
10-Q/A, recent Current Reports on Forms 8-K and 8-K/A, our
Registration Statement on Form S-3, and other SEC filingsdiscuss some
of the important risk factors that may affect our business, results
of operations and financial condition. We undertake no obligation to
revise or update publicly any forward-looking statements for any
For more information, please click here
Copyright © Arrowhead Research CorporationIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Artificial synapse rivals biological ones in energy consumption June 21st, 2016
Nanometrics Announces Upcoming Investor Events May 10th, 2016
Soft decoupling of organic molecules on metal June 23rd, 2016
FEI and University of Liverpool Announce QEMSCAN Research Initiative: University of Liverpool will utilize FEIís QEMSCAN technology to gain a better insight into oil and gas reserves & potentially change the approach to evaluating them June 22nd, 2016
French Research Team Helps Extend MRI Detection of Diseases & Lower Health-Care Costs: CEA, INSERM and G2ELab Brings Grenoble Regionís Expertise In Advanced Medicine & Magnetism Applications to H2020 IDentIFY Project June 21st, 2016